Back

Commensal bacteria inhibit viral infections via a tryptophan metabolite

Jiang, D.; Soo, N.; Tan, C. Y.; Dankwa, S.; Wang, H.-Y.; Theriot, B. S.; Xue, K.; Hill, D.; Ardeshir, A.; Bain, J. R.; Heston, S. M.; Hurst, J. H.; Siddiqui, N. Y.; Van Rompay, K. K. A.; Cervantes-Barragan, L.; Smith, J. P.; Song, R.; Roper, J.; Kelly, M. S.; Hudgens, M. G.; De Paris, K.; Permar, S. R.; Goswami, R.; Surana, N. K.

2025-05-12 microbiology
10.1101/2024.04.21.589969 bioRxiv
Show abstract

Clinical outcomes following viral exposures exhibit substantial interindividual variability. Although developing evidence suggests commensal bacteria modulate viral infections, the specific bacteria and mechanisms remain underexplored. Here we define a pathway by which viral infections are inhibited by specific tryptophan-catabolizing bacteria. Using HIV as a model, we bioinformatically associated and experimentally validated several bacterial species that inhibited viral replication. This activity required the aromatic amino acid aminotransferase (ArAT) to metabolize tryptophan into 3-indolelactic acid, which agonizes the aryl hydrocarbon receptor (AhR). Given that AhR regulates multiple viral infections, we found that commensal bacteria also inhibit cytomegalovirus (CMV) in an ArAT-dependent manner. Finally, we confirmed that ArAT is associated with protection against disease outcomes in three distinct human cohorts at-risk for HIV, CMV, or symptomatic COVID-19. Taken together, our results provide mechanistic insight into how commensal bacteria impact viral infections, thereby adding to an emerging field focused on host-commensal-virus interactions.

Published in Nature Communications (predicted rank #2) · training set

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above